Bouke C. de Jong

11.5k total citations · 1 hit paper
192 papers, 6.1k citations indexed

About

Bouke C. de Jong is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Bouke C. de Jong has authored 192 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 162 papers in Infectious Diseases, 150 papers in Epidemiology and 57 papers in Surgery. Recurrent topics in Bouke C. de Jong's work include Tuberculosis Research and Epidemiology (150 papers), Mycobacterium research and diagnosis (125 papers) and Infectious Diseases and Tuberculosis (33 papers). Bouke C. de Jong is often cited by papers focused on Tuberculosis Research and Epidemiology (150 papers), Mycobacterium research and diagnosis (125 papers) and Infectious Diseases and Tuberculosis (33 papers). Bouke C. de Jong collaborates with scholars based in Belgium, United States and Gambia. Bouke C. de Jong's co-authors include Sébastien Gagneux, Leen Rigouts, Martín Antonio, Armand Van Deun, Peter M. Small, Philip C. Hopewell, Kathryn DeRiemer, Stefan Niemann, Conor J. Meehan and Richard A. Adegbola and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Bouke C. de Jong

180 papers receiving 6.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Variable host–pathogen compatibility in Mycobacterium tuberculosis

2006 725 citations Sébastien Gagneux, Bouke C. de Jong et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bouke C. de Jong Belgium	38	5.2k	4.7k	2.3k	1.1k	387	192	6.1k
Roland Diel Germany	46	5.7k 1.1×	5.1k 1.1×	3.1k 1.4×	561 0.5×	145 0.4×	148	6.8k
Max Salfinger United States	38	4.3k 0.8×	4.1k 0.9×	1.8k 0.8×	723 0.7×	470 1.2×	113	5.7k
Sabine Rüsch–Gerdes Germany	54	7.1k 1.4×	7.0k 1.5×	3.3k 1.4×	1.1k 1.1×	461 1.2×	158	8.4k
Åse Bengård Andersen Denmark	46	5.2k 1.0×	4.2k 0.9×	2.2k 0.9×	954 0.9×	194 0.5×	214	7.1k
Alexander S. Pym South Africa	38	6.1k 1.2×	4.9k 1.0×	2.0k 0.9×	1.5k 1.4×	585 1.5×	85	7.2k
Yanlin Zhao China	34	3.4k 0.7×	3.0k 0.6×	1.3k 0.5×	556 0.5×	296 0.8×	169	4.1k
Doris Hillemann Germany	32	3.9k 0.7×	3.5k 0.7×	1.9k 0.8×	1.0k 1.0×	315 0.8×	87	5.0k
Leen Rigouts Belgium	37	3.7k 0.7×	3.5k 0.7×	1.6k 0.7×	717 0.7×	356 0.9×	172	4.3k
Kathleen D. Eisenach United States	50	7.5k 1.4×	7.0k 1.5×	3.8k 1.6×	1.3k 1.2×	490 1.3×	115	8.9k
Gunilla Källenius Sweden	45	3.3k 0.6×	4.1k 0.9×	1.2k 0.5×	1.2k 1.1×	410 1.1×	155	6.7k

Countries citing papers authored by Bouke C. de Jong

Since Specialization

Citations

This map shows the geographic impact of Bouke C. de Jong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bouke C. de Jong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bouke C. de Jong more than expected).

Fields of papers citing papers by Bouke C. de Jong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bouke C. de Jong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bouke C. de Jong. The network helps show where Bouke C. de Jong may publish in the future.

Co-authorship network of co-authors of Bouke C. de Jong

This figure shows the co-authorship network connecting the top 25 collaborators of Bouke C. de Jong. A scholar is included among the top collaborators of Bouke C. de Jong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bouke C. de Jong. Bouke C. de Jong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Souleymane, Mahamadou Bassirou, Tom Decroo, Eric Adéhossi, et al.. (2025). Using linezolid as a substitute for the injectable in case of ototoxicity is safer and as effective as all-oral treatment for rifampicin-resistant TB. PubMed. 2(8). 450–458.

Gasana, Janvier, Tom Decroo, Bart K. M. Jacobs, et al.. (2025). High-dose amikacin in the first week of all-oral rifampicin-resistant TB treatment is safe: a single-arm trial. PubMed. 2(11). 655–661.

Windels, Etthel M., Bouke C. de Jong, Conor J. Meehan, et al.. (2025). Onset of infectiousness explains differences in transmissibility across Mycobacterium tuberculosis lineages. Epidemics. 51. 100821–100821. 2 indexed citations

Kiselinova, Maja, Leen Rigouts, Andre Nyandwe Hamama Bulabula, et al.. (2025). Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting. Clinical Infectious Diseases. 82(2). 274–281.

Piubello, Alberto, Achilleas Tsoumanis, Harry van Loen, et al.. (2024). Feasibility and accuracy of mobile QT interval monitoring strategies in bedaquiline‐enhanced prophylactic leprosy treatment. Clinical and Translational Science. 17(8). e13861–e13861. 1 indexed citations

Mulders, Wim, Matthias Merker, Stefan Niemann, et al.. (2024). Refined understanding of the impact of the Mycobacterium tuberculosis complex diversity on the intrinsic susceptibility to pretomanid. Microbiology Spectrum. 12(3). e0007024–e0007024. 9 indexed citations

Lempens, Pauline, Armand Van Deun, K. J. M. Aung, et al.. (2023). Borderline rpoB mutations transmit at the same rate as common rpoB mutations in a tuberculosis cohort in Bangladesh. Microbial Genomics. 9(9).

Souleymane, Mahamadou Bassirou, Alberto Piubello, Achilleas Tsoumanis, et al.. (2023). High rate of adverse drug reactions with a novel tuberculosis re-treatment regimen combining triple doses of both isoniazid and rifampicin. International Journal of Infectious Diseases. 133. 78–81. 8 indexed citations

Souleymane, Mahamadou Bassirou, Tom Decroo, Saïdou Mamadou, et al.. (2022). Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study. International Health. 15(3). 258–264. 2 indexed citations

10.

Ortuño‐Gutiérrez, Nimer, et al.. (2022). High yield of retrospective active case finding for leprosy in Comoros. PLoS neglected tropical diseases. 16(3). e0010158–e0010158. 6 indexed citations

11.

Ortuño‐Gutiérrez, Nimer, et al.. (2022). Less is more: Developing an approach for assessing clustering at the lower administrative boundaries that increases the yield of active screening for leprosy in Bihar, India. PLoS neglected tropical diseases. 16(9). e0010764–e0010764. 4 indexed citations

12.

Coscollá, Mireia, Boatema Ofori-Anyinam, Isaac Darko Otchere, et al.. (2021). Mycobacterium tuberculosis complex lineage 5 exhibits high levels of within-lineage genomic diversity and differing gene content compared to the type strain H37Rv. Microbial Genomics. 7(7). 12 indexed citations

13.

Lynen, Lutgarde, et al.. (2021). Pretomanid for tuberculosis: a systematic review. Clinical Microbiology and Infection. 28(1). 31–42. 50 indexed citations

14.

Souleymane, Mahamadou Bassirou, Alberto Piubello, Nimer Ortuño‐Gutiérrez, et al.. (2020). High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss. European Respiratory Journal. 57(1). 2002250–2002250. 12 indexed citations

15.

Farhat, Maha, Luca Freschi, Róger Calderón, et al.. (2019). GWAS for quantitative resistance phenotypes in Mycobacterium tuberculosis reveals resistance genes and regulatory regions. Nature Communications. 10(1). 2128–2128. 105 indexed citations

16.

Ssengooba, Willy, Conor J. Meehan, Deus Lukoye, et al.. (2016). Whole genome sequencing to complement tuberculosis drug resistance surveys in Uganda. Infection Genetics and Evolution. 40. 8–16. 29 indexed citations

17.

Nahid, Payam, Leah G. Jarlsberg, Bouke C. de Jong, et al.. (2011). Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis. BMC Infectious Diseases. 11(1). 1–1. 245 indexed citations

18.

Meijvis, Sabine C A, Bjorn L. Herpers, Henrik Endeman, et al.. (2010). Mannose-binding lectin (MBL2) and ficolin-2 (FCN2) polymorphisms in patients on peritoneal dialysis with staphylococcal peritonitis. Nephrology Dialysis Transplantation. 26(3). 1042–1045. 13 indexed citations

19.

Nahid, Payam, Leah C. Gonzalez, Bouke C. de Jong, et al.. (2007). Treatment Outcomes of Patients with HIV and Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 175(11). 1199–1206. 99 indexed citations

20.

Hill, Philip C., David Jeffries, Roger H. Brookes, et al.. (2007). Using ELISPOT to Expose False Positive Skin Test Conversion in Tuberculosis Contacts. PLoS ONE. 2(1). e183–e183. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact